Akci\u011fer Kanserinde Diren\u00e7le M\u00fccadelede Yeni Umut: MET ve EGFR \u0130nhibit\u00f6rlerinin Kombinasyonu<\/p>\n
Akci\u011fer kanseri, \u00f6zellikle de k\u00fc\u00e7\u00fck h\u00fccre d\u0131\u015f\u0131 akci\u011fer kanseri (NSCLC), d\u00fcnya genelinde en y\u00fcksek \u00f6l\u00fcm oranlar\u0131na sahip kanser t\u00fcrlerinden biridir. Bu kanser t\u00fcr\u00fcnde EGFR (Epidermal B\u00fcy\u00fcme Fakt\u00f6r\u00fc Resept\u00f6r\u00fc) mutasyonlar\u0131na sahip hastalar, EGFR tirozin kinaz inhibit\u00f6rleri (EGFR-TKI\u2019lar\u0131) ile tedaviye erken evrede iyi yan\u0131t verse de, diren\u00e7 geli\u015fimi tedavi ba\u015far\u0131s\u0131n\u0131 s\u0131n\u0131rland\u0131rmaktad\u0131r. Son y\u0131llarda ortaya \u00e7\u0131kan ara\u015ft\u0131rmalar, hastalar\u0131n tedavi ba\u015far\u0131s\u0131n\u0131 art\u0131rmak i\u00e7in MET yolaklar\u0131n\u0131n hedeflenmesinin \u00f6nemini vurgulamaktad\u0131r. MET tirozin kinaz inhibit\u00f6rleri (MET-TKI\u2019lar\u0131) ile EGFR-TKI\u2019lar\u0131n\u0131n kombinasyonu, bu diren\u00e7 mekanizmalar\u0131n\u0131 a\u015fmaya y\u00f6nelik yeni bir strateji olarak kar\u015f\u0131m\u0131za \u00e7\u0131kmaktad\u0131r.<\/p>\n
Son d\u00f6nemde BMC Cancer dergisinde yay\u0131mlanan kapsaml\u0131 bir sistematik inceleme ve meta-analiz, MET-TKI ve EGFR-TKI kombinasyonlar\u0131n\u0131n NSCLC hastalar\u0131nda sa\u011flad\u0131\u011f\u0131 faydalar\u0131 ve riskleri mercek alt\u0131na alm\u0131\u015ft\u0131r. Analiz kapsam\u0131nda, EGFR-TKI tedavisi sonras\u0131 MET kaynakl\u0131 diren\u00e7 geli\u015fen 562 hastan\u0131n verileri de\u011ferlendirilmi\u015f, t\u00fcm\u00f6r cevab\u0131, sa\u011fkal\u0131m s\u00fcresi ve yan etkiler detayl\u0131 olarak incelenmi\u015ftir. Bu yenilik\u00e7i ara\u015ft\u0131rma, molek\u00fcler diren\u00e7 profiline uygun tedavi yakla\u015f\u0131mlar\u0131n\u0131n \u015fekillenmesinde \u00f6nemli bir referans noktas\u0131 olma \u00f6zelli\u011fi ta\u015f\u0131maktad\u0131r.<\/p>\n
\u00c7al\u0131\u015fman\u0131n temel sonu\u00e7lar\u0131 umut vericidir. MET-TKI ve EGFR-TKI kombinasyon terapisine yan\u0131t veren hastalar\u0131n oran\u0131 (ORR %49,2) ve hastal\u0131k kontrol oran\u0131 (DCR %78,6), yakla\u015f\u0131k yar\u0131s\u0131n\u0131n t\u00fcm\u00f6r k\u00fc\u00e7\u00fclmesi, \u00fc\u00e7te ikisinin ise hastal\u0131\u011f\u0131n kontrol\u00fc elde etti\u011fini g\u00f6stermektedir. Ayr\u0131ca yan\u0131t s\u00fcresi ortalama 6,85 ay ve ilerlemesiz sa\u011fkal\u0131m s\u00fcresi yakla\u015f\u0131k 5,62 ay olarak rapor edilmi\u015ftir. Bu s\u00fcreler, t\u00fcm\u00f6r gerilemesinin anlaml\u0131 ve kal\u0131c\u0131 oldu\u011funu ve hastal\u0131\u011f\u0131n ilerlemesinin \u00f6nemli \u00f6l\u00e7\u00fcde gecikti\u011fini ortaya koymaktad\u0131r.<\/p>\n
\u0130nceleme, tedavide kullan\u0131lan EGFR-TKI ku\u015faklar\u0131n\u0131n farkl\u0131l\u0131\u011f\u0131n\u0131 a\u00e7\u0131k\u00e7a ortaya koymaktad\u0131r. \u00d6zellikle \u00fc\u00e7\u00fcnc\u00fc ku\u015fak EGFR-TKI\u2019lar\u0131yla (\u00f6rn. osimertinib) MET-TKI kombinasyonlar\u0131n\u0131n, birinci ku\u015faklara k\u0131yasla yan\u0131t oranlar\u0131nda ve hastal\u0131\u011f\u0131n kontrol\u00fcnde daha y\u00fcksek etkinlik sundu\u011fu g\u00f6zlenmi\u015ftir. T790M mutasyonu negatif ancak MET ba\u011f\u0131ml\u0131 diren\u00e7 geli\u015ftiren hastalarda, \u00fc\u00e7\u00fcnc\u00fc ku\u015fak kombinasyonlar\u0131n %56,8 ORR ve %81,6 DCR oranlar\u0131yla, birinci ku\u015fak kombinasyonlar\u0131na g\u00f6re (ORR %47,8, DCR %75) daha iyi performans sergiledi\u011fi belirlenmi\u015ftir. \u0130lerlemesiz sa\u011fkal\u0131mda (mPFS) ise \u00fc\u00e7\u00fcnc\u00fc ku\u015fak kombinasyonlar 7,45 ay ile 4,55 ay\u0131 a\u015fm\u0131\u015f ve bu fark istatistiksel anlamda anlaml\u0131 d\u00fczeye yakla\u015fm\u0131\u015ft\u0131r (p=0,05).<\/p>\n
MET inhibit\u00f6rlerinin etkinlik kar\u015f\u0131la\u015ft\u0131rmas\u0131 da olduk\u00e7a ayd\u0131nlat\u0131c\u0131d\u0131r. Capmatinib, savolitinib ve tepotinib gibi \u00fc\u00e7 \u00f6nde gelen MET-TKI\u2019si, t\u00fcm\u00f6r yan\u0131t oranlar\u0131nda (%48-51 aras\u0131) benzer performans g\u00f6stermi\u015ftir. Hastal\u0131k kontrol oranlar\u0131nda baz\u0131 farkl\u0131l\u0131klar (savolitinib %84,9, tepotinib %63,3) g\u00f6zlense de, genel olarak bu farkl\u0131l\u0131klar t\u00fcm sonu\u00e7lara do\u011frudan yans\u0131mam\u0131\u015f ve klinik anlamda e\u015f de\u011fer kabul edilmi\u015ftir. Yan\u0131t s\u00fcresi ve ilerlemenin gecikme s\u00fcresi a\u00e7\u0131s\u0131ndan da MET inhibit\u00f6rleri aras\u0131nda \u00f6nemli bir ayr\u0131m g\u00f6zlenmemi\u015ftir.<\/p>\n
G\u00fcvenlik ve yan etkiler bak\u0131m\u0131ndan ise se\u00e7ici farkl\u0131l\u0131klar \u00f6n plana \u00e7\u0131kmaktad\u0131r. MET-TKI kombinasyonlar\u0131n\u0131n en yayg\u0131n yan etkilerinden biri karaci\u011fer enzimlerinde y\u00fckselmedir. Capmatinib grubunda AST ve ALT y\u00fckselmeleri di\u011fer MET-TKI\u2019lar\u0131na g\u00f6re daha az g\u00f6r\u00fclmekte; \u00f6rne\u011fin AST y\u00fckselmesi capmatinib ile %12,8 iken, savolitinib\u2019te %19 ve tepotinib\u2019te %17,4 olarak kaydedilmi\u015ftir. Ayr\u0131ca ciddi (grade \u22653) tedavi ili\u015fkili yan etki oranlar\u0131 capmatinib ile yakla\u015f\u0131k %30 iken, savolitinib\u2019de %46,7 ve tepotinib\u2019te %41,2\u2019dir. Bu veriler, \u00f6zellikle karaci\u011fer hastal\u0131\u011f\u0131 olan veya uzun s\u00fcreli tedavi almas\u0131 planlanan hastalar i\u00e7in MET-TKI se\u00e7iminin \u00f6nemini vurgulamaktad\u0131r.<\/p>\n
Bu verilerin \u0131\u015f\u0131\u011f\u0131nda, MET-TKI ve EGFR-TKI kombinasyonlar\u0131n\u0131n NSCLC tedavisine entegre edilmesi, molek\u00fcler diren\u00e7 mekanizmalar\u0131n\u0131 hedefleme a\u00e7\u0131s\u0131ndan \u00f6nemli bir yakla\u015f\u0131m olarak \u00f6ne \u00e7\u0131kmaktad\u0131r. MET yolundaki amplifikasyon veya mutasyonlar EGFR-TKI direncinin \u00f6nde gelen nedenlerindendir. Bu mutasyonlar, PI3K\/AKT ve MAPK gibi h\u00fccre i\u00e7i sinyal yollar\u0131n\u0131 yeniden aktive ederek EGFR inhibit\u00f6rlerine kar\u015f\u0131 bypass sa\u011flayabilir. MET-TKI\u2019lar\u0131n kombine kullan\u0131m\u0131, bu ka\u00e7\u0131\u015f yollar\u0131n\u0131 bloke ederek hastal\u0131\u011f\u0131n kontrol\u00fcn\u00fc yeniden sa\u011flamaktad\u0131r.<\/p>\n
\u00dc\u00e7\u00fcnc\u00fc ku\u015fak EGFR-TKI\u2019lar\u0131, T790M mutasyonu ba\u015fta olmak \u00fczere diren\u00e7 olu\u015fturan mutasyonlara kar\u015f\u0131 daha spesifik ve etkili bir inhibisyon sa\u011flar. Bu nedenle, MET-TKI\u2019larla birlikte kullan\u0131mlar\u0131 daha \u00fcst\u00fcn tedavi sonu\u00e7lar\u0131na ula\u015f\u0131lmas\u0131n\u0131 m\u00fcmk\u00fcn k\u0131labilir ki meta-analiz bu varsay\u0131m\u0131 destekler niteliktedir. Ancak, bu bulgular\u0131n g\u00fc\u00e7lendirilmesi ve kesinle\u015ftirilmesi i\u00e7in prospektif, randomize kontroll\u00fc \u00e7al\u0131\u015fmalara ihtiya\u00e7 vard\u0131r.<\/p>\n
Tedavi g\u00fcvenli\u011fi a\u00e7\u0131s\u0131ndan MET-TKI\u2019larla ili\u015fkili hepatotoksisite dikkate al\u0131nmal\u0131d\u0131r. \u00d6zellikle uzun s\u00fcreli tedavi gerektiren hastalarda karaci\u011fer fonksiyonlar\u0131n\u0131n yak\u0131ndan takibi ve yan etki profiline g\u00f6re ila\u00e7 se\u00e7imi hasta konforunu art\u0131rabilir. Capmatinib\u2019in g\u00f6rece daha iyi hepatoprotektif profili, klinik tercihleri etkileyen \u00f6nemli bir fakt\u00f6r olabilir.<\/p>\n
Ara\u015ft\u0131rman\u0131n baz\u0131 k\u0131s\u0131tlamalar\u0131 da mevcuttur. Meta-analizde yer alan \u00e7al\u0131\u015fmalar hasta se\u00e7im kriterleri, MET de\u011fi\u015fikliklerinin tan\u0131m\u0131 ve tedavi protokolleri a\u00e7\u0131s\u0131ndan heterojenlik g\u00f6stermektedir. Ayr\u0131ca, farkl\u0131 MET-TKI ve EGFR-TKI kombinasyonlar\u0131n\u0131n do\u011frudan kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131 randomize \u00e7al\u0131\u015fmalar\u0131n eksikli\u011fi, kesin klinik kararlar\u0131n verilmesini s\u0131n\u0131rlamaktad\u0131r. Bunlar, gelecekteki ara\u015ft\u0131rmalar i\u00e7in kritik a\u00e7\u0131klar olarak de\u011ferlendirilmelidir.<\/p>\n
Yine de, bu bulgular NSCLC tedavisinde diren\u00e7 mekanizmalar\u0131yla m\u00fccadelede yeni bir d\u00f6nemin habercisidir. Ki\u015fiye \u00f6zg\u00fc, molek\u00fcler alt gruplara dayal\u0131 hedefe y\u00f6nelik tedavi yakla\u015f\u0131mlar\u0131, tedavi ba\u015far\u0131s\u0131n\u0131 art\u0131rmakta ve hastalar\u0131n ya\u015fam kalitesini y\u00fckseltmektedir. MET ve EGFR inhibit\u00f6rlerinin kombinasyonu, diren\u00e7 bariyerlerini par\u00e7alayarak umut vadeden sonu\u00e7lar sunmaktad\u0131r.<\/p>\n
Gelecekte, bu kombinasyonlar\u0131n hangi hasta gruplar\u0131nda, ne zaman ve hangi dozda kullan\u0131laca\u011f\u0131; immunoterapi gibi di\u011fer tedavilerle entegrasyon yollar\u0131; diren\u00e7 biyobelirte\u00e7lerinin belirlenmesi gibi konulara yo\u011funla\u015fan klinik ara\u015ft\u0131rmalar beklenmektedir. Bu \u00e7ok y\u00f6nl\u00fc yakla\u015f\u0131m, daha uzun sa\u011fkal\u0131m ve hastal\u0131k kontrol\u00fc sa\u011flayan tedavi standartlar\u0131n\u0131n geli\u015ftirilmesi a\u00e7\u0131s\u0131ndan b\u00fcy\u00fck \u00f6nem ta\u015f\u0131yacakt\u0131r.<\/p>\n
Lung kanserinde, \u00f6zellikle NSCLC\u2019de, yeni tedavi stratejilerinin geli\u015ftirilmesi hayat kurtar\u0131c\u0131d\u0131r. MET-TKI ve EGFR-TKI kombinasyonlar\u0131, diren\u00e7 fakt\u00f6rlerini hedef alma konusunda \u00f6nemli bir d\u0131\u015favurumdur. Klinik uygulamalara entegrasyonu, tedavi ba\u015far\u0131s\u0131n\u0131 art\u0131rarak hastalara yeni umut kap\u0131lar\u0131 aralamaktad\u0131r.<\/p>\n
Sonu\u00e7 olarak, kanser tedavisinde molek\u00fcler mekanizmalar\u0131 anlamak ve bunlara y\u00f6nelik m\u00fchendislik yapmak, ila\u00e7 direncinin \u00fcstesinden gelmede kritik bir yakla\u015f\u0131md\u0131r. MET ve EGFR inhibit\u00f6rlerinin birle\u015fimi, ki\u015fiselle\u015ftirilmi\u015f onkolojide \u00f6nemli bir d\u00f6n\u00fcm noktas\u0131d\u0131r ve \u00f6n\u00fcm\u00fczdeki y\u0131llarda NSCLC tedavisinde standartlara y\u00f6n verecektir.<\/p>\n
—<\/p>\n
Ara\u015ft\u0131rma Konusu<\/strong>: Makale Ba\u015fl\u0131\u011f\u0131<\/strong>: Haberin Yay\u0131n Tarihi<\/strong>: Web References<\/strong>: Doi Referans<\/strong>: Resim Credits<\/strong>: Anahtar Kelimeler<\/strong>: Akci\u011fer Kanserinde Diren\u00e7le M\u00fccadelede Yeni Umut: MET ve EGFR \u0130nhibit\u00f6rlerinin Kombinasyonu Akci\u011fer kanseri, \u00f6zellikle de k\u00fc\u00e7\u00fck h\u00fccre d\u0131\u015f\u0131 akci\u011fer kanseri (NSCLC), d\u00fcnya genelinde en y\u00fcksek \u00f6l\u00fcm oranlar\u0131na sahip kanser t\u00fcrlerinden biridir. Bu kanser t\u00fcr\u00fcnde EGFR (Epidermal B\u00fcy\u00fcme Fakt\u00f6r\u00fc Resept\u00f6r\u00fc) mutasyonlar\u0131na sahip hastalar, EGFR tirozin kinaz inhibit\u00f6rleri (EGFR-TKI\u2019lar\u0131) ile tedaviye erken evrede iyi yan\u0131t verse de,…<\/p>\n","protected":false},"author":1,"featured_media":3125,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_wpan_schema_json_ld":"","_wpan_ai_seo_metadata":"","_wpan_ai_seo_status":"","_wpan_ai_seo_policy":"","_wpan_ai_seo_faq_block":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[1381,1382,1384,1380,1383],"tmauthors":[],"class_list":{"0":"post-3124","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-kanser","8":"tag-egfr-tki-ve-met-tki-direnc-mekanizmalari","9":"tag-kucuk-hucre-disi-akciger-kanseri-molekuler-hedef-tedavisi","10":"tag-met-bagimli-direnc-tedavi-stratejileri","11":"tag-nsclc-tedavisinde-met-ve-egfr-inhibitor-kombinasyonlari","12":"tag-ucuncu-kusak-egfr-inhibitorlerinin-etkinligi"},"jetpack_featured_media_url":"https:\/\/haber360.com\/wp-content\/uploads\/2025\/04\/MET-ve-EGFR-Inhibitorleri-NSCLC-Tedavisini-Guclendiriyor-1744982070.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/comments?post=3124"}],"version-history":[{"count":0,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3124\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media\/3125"}],"wp:attachment":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media?parent=3124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/categories?post=3124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tags?post=3124"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tmauthors?post=3124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nCombination therapy using MET tyrosine kinase inhibitors and EGFR tyrosine kinase inhibitors in NSCLC patients with EGFR mutations and acquired MET alterations.<\/p>\n
\nMET tyrosine kinase inhibitors in combination with EGFR tyrosine kinase inhibitors in NSCLC patients with EGFR mutations and acquired MET alterations: a systematic review and meta-analysis.<\/p>\n
\n2025<\/p>\n
\nhttps:\/\/bmcancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14145-5<\/p>\n
\nhttps:\/\/doi.org\/10.1186\/s12885-025-14145-5<\/p>\n
\nScienmag.com<\/p>\n
\nacquired resistance mechanisms, clinical meta-analysis, NSCLC, combined cancer therapies, disease control rate in NSCLC, EGFR tyrosine kinase inhibitors, MET tyrosine kinase inhibitors, molecular resistance profiles, non-small cell lung cancer treatment, objective response rate in cancer, strategic drug combinations in oncology, targeted therapy for lung cancer, therapeutic outcomes in lung cancer<\/p>\n","protected":false},"excerpt":{"rendered":"